Darolutamide in addition to docetaxel and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer
Darolutamide in addition to docetaxel and androgen deprivation therapy (ADT) is in clinical development for the treatment of patients with metastatic hormone-sensitive prostate cancer. Prostate cancer affects the prostate (a small gland in the pelvis only found in men), but symptoms generally do not appear until the prostate is large enough to affect the urethra (the tube connecting the bladder to outside the body). Metastatic prostate cancer is when the cancer spreads to another part of the body. Common symptoms of metastatic prostate cancer include bone pain and fatigue.
Androgen receptors promote prostate cancer growth, darolutamide is a nonsteroidal androgen receptor inhibitor and can prevent cancer growth. Docetaxel in combination with ADT are commonly used in practice, the addition of darolutamide (taken orally) may improve survival and offer an additional treatment option for those patients with metastatic hormone-sensitive prostate cancer.